CN1824204A - Medicinal composition for treating acute urarthritis and its preparation method - Google Patents
Medicinal composition for treating acute urarthritis and its preparation method Download PDFInfo
- Publication number
- CN1824204A CN1824204A CN 200510022681 CN200510022681A CN1824204A CN 1824204 A CN1824204 A CN 1824204A CN 200510022681 CN200510022681 CN 200510022681 CN 200510022681 A CN200510022681 A CN 200510022681A CN 1824204 A CN1824204 A CN 1824204A
- Authority
- CN
- China
- Prior art keywords
- radix
- cortex phellodendri
- preparation
- pharmaceutical composition
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating acute gouty arthritis is prepared from 6 Chinese-medicinal materials including coptis root, scutellaria root, rhubarb, China root, etc through extracting in water and/or alcohol, concentrating and preparing any form.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of acute gouty arthritis and preparation method thereof, but be specifically related to prevent and treat the preparation method of the Chinese medicine composition and the industrializing implementation thereof of acute gouty arthritis.
Background technology
Gout causes owing to heritability or the acquired cause of disease cause purine metabolism obstacle and blood uric acid to continue to raise, is one group of disease of tissue injury due to long-term purine metabolic disturbance, blood uric acid increase.Think that in the past gout is the common epidemic diseases in west, sickness rate accounts for the 0.13-0.37% of total population, and in recent years Epidemiological study finds, Asians's gout sickness rate even be higher than the westerner.Along with people's living standard raising, sickness rate is the trend that rises year by year.According to statistics, in China big and medium-sized cities, sickness rate is near foreign level.
But the western medical treatment relief of symptoms can only take stopgap measures and can not effect a permanent cure, and toxic and side effects is bigger.Anti-gout drugs commonly used has colchicine and allopurinol and indometacin, ibuprofen, diclofenac etc.
The traditional Chinese medical science is classified gout as the numbness disease.Chinese medicine prevents that gout from showing its superiority gradually in recent years, and untoward reaction is few.Mainly be divided into determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, debate disease by controlling.Specially side's plus-minus is treated and the folk prescription single therapy.Wait with removing dampness, let out turbid detoxifcation, depressed liver-energy dispersing and QI regulating, kidney tonifying spleen invigorating, activating meridians to stop pain as " strong kidney dispel pain spirit ", make goat fundamentally controlled and effect a radical cure.
Summary of the invention
The invention provides a kind of Chinese medicine composition for the treatment of acute gouty arthritis and preparation method thereof, its objective is will be by optimizing preparation prescription and using modern extraction process, prepares stable curative effect, quality controllable Chinese medicine preparation.
For achieving the above object, the technical scheme that pharmaceutical composition of the present invention adopts is: a kind of pharmaceutical composition for the treatment of acute gouty arthritis, mainly form by the crude drug of following parts by weight:
Cortex Phellodendri or Rhizoma Coptidis 1-15 part;
Radix Scutellariae 1-15 part;
Radix Et Rhizoma Rhei 1-15 part;
Radix Stephaniae Tetrandrae 1-13 part;
Rhizoma Smilacis Glabrae 5-25 part;
Pseudobulbus Cremastrae Seu Pleiones 5-25 part.
Related content in the technique scheme is explained as follows:
1, the crude drug prescription of aforementioned pharmaceutical compositions is a necessary component of the present invention, and the present invention can increase other auxiliary medicaments on this basis, and does not change the essence of pharmaceutical composition of the present invention.The auxiliary medicaments that is increased can be determined by existing ordinary skill.The auxiliary medicaments that is increased can be determined by existing ordinary skill.
2, in the such scheme, the Cortex Phellodendri in the described crude drug is divided into Cortex Phellodendri and Cortex Phellodendri two big classes, and selects Cortex Phellodendri best results wherein.
3, in the such scheme, after Cortex Phellodendri was selected Cortex Phellodendri for use, each crude drug amount ranges preferably was:
Cortex Phellodendri 2-6 part;
Radix Scutellariae 2-5 part;
Radix Et Rhizoma Rhei 2-8 part;
Radix Stephaniae Tetrandrae 2-7 part;
Rhizoma Smilacis Glabrae 10-15 part;
Pseudobulbus Cremastrae Seu Pleiones 10-15 part.
4, in the such scheme, after Cortex Phellodendri was selected Cortex Phellodendri for use, the amount ranges of each crude drug the best was:
Cortex Phellodendri 3-4 part;
4 parts of Radix Scutellariaes;
Radix Et Rhizoma Rhei 4-6 part;
Radix Stephaniae Tetrandrae 4-5 part;
Rhizoma Smilacis Glabrae 12-14 part;
Pseudobulbus Cremastrae Seu Pleiones 11-13 part.
For achieving the above object, the technical scheme that process for preparing medicine of the present invention adopts is: a kind of preparation of drug combination method for the treatment of acute gouty arthritis, on the basis of above crude drug prescription, adopt following steps: earlier with Cortex Phellodendri, Radix Scutellariae, Radix Et Rhizoma Rhei, Radix Stephaniae Tetrandrae, Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones, water and/or alcohol extraction, concentrated extracting solution then, drying finally obtains any preparation on the pharmaceutics.
Related content in the technique scheme is explained as follows:
1, in the such scheme, way is preferably: to the Cortex Phellodendri in the crude drug, Radix Stephaniae Tetrandrae, Radix Scutellariae, Radix Et Rhizoma Rhei alcohol extraction, and Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones water extraction, concentrated extracting solution merges water extract and alcohol extract, drying then.Specifically can adopt following steps:
(1), get Cortex Phellodendri, Radix Stephaniae Tetrandrae medical material, add alcohol reflux and extract, pure liquid, further concentrate pure liquid, alcohol extraction concentrated solution A;
(2), get Radix Et Rhizoma Rhei, radix scutellariae medicinal materials, add that alcohol reflux extracts and concentrate alcohol extraction concentrated solution B;
(3), the Poria that fetches earth, Pseudobulbus Cremastrae Seu Pleiones medical material, extracting in water and concentrate water extracting liquid C;
(4), concentrated solution A, B, C are merged, drying is granulated or pill, and is encapsulated, the active component of pharmaceutical composition of the present invention.
In this programme, described pure liquid is ethanol liquid, and weight percent concentration is 55%---95%, is preferably 60%---75%.Described drying means is drying under reduced pressure or spray drying.Described method of granulating is wet granulation or dry granulation or spray-drying process or fluidized bed granulation.Described pill method is for extruding spheronization or centrifugal-fluidization process or coating pan method or the granulating coated method of ebullated bed.
Therapeutic mechanism of the present invention is: the Cortex Phellodendri heat clearing and damp drying, and eliminating fire and detoxication is monarch drug; Be aided with Radix Et Rhizoma Rhei, Radix Scutellariae strengthen the purging heat merit of clots absorbing, be ministerial drug; The Radix Stephaniae Tetrandrae diuretic is swollen clearly, expelling wind and removing dampness, and Pseudobulbus Cremastrae Seu Pleiones, Rhizoma Smilacis Glabrae detumescence powder detoxifcation, the three is adjuvant altogether.All medicines share, and have the heat clearing and damp drying pathogenic fire purging, the effect of clots absorbing removing obstruction in the collateral to relieve pain.
Evidence, technical scheme of the present invention according to theory of Chinese medical science with Cortex Phellodendri, Radix Et Rhizoma Rhei, Radix Scutellariae, Radix Stephaniae Tetrandrae, Pseudobulbus Cremastrae Seu Pleiones, the Rhizoma Smilacis Glabrae prescription, by heat-clearing and toxic substances removing, the clots absorbing that purges heat, the synergism of aspects such as reducing swelling and alleviating pain, reach the treatment acute gouty arthritis purpose.Designed system's extraction and separation process makes the effective site enrichment, has prepared the medicine of treatment acute gouty arthritis.
The following is the main pharmacodynamics data of this preparation:
1, pharmaceutical composition of the present invention is to the inhibitory action of rat paw edema due to the micro-crystal type uric acid sodium
Adopt micro-crystal type uric acid sodium to cause rat paw edema method (volumetric method measurement) and make the gouty arthritis model, irritate after stomach is equivalent to the medicine of the present invention (claiming " mountain yellow capsule " again) of raw medicinal herbs 8.0g/kg, 4.0g/kg and 2.0g/kg for rat for three days on end, 2～6 hours paw swelling of high, middle dosage treated animal and model control group are relatively, remarkable reduction (P＜0.05～0.001) is all arranged, the basic normal level that recovers in the 5h after causing inflammation; Low dose group swelling rate of 2h after administration also has obvious reduction (P＜0.05), basic behind the 24h near normal, show that the medicine of the present invention (claiming " mountain yellow capsule " again) of irritating the stomach doses causes the rat foot swelling to micro-crystal type uric acid sodium and has certain inhibitory action, prompting this product has certain preventive and therapeutic effect to gouty arthritis.
2, pharmaceutical composition of the present invention is to the preventive and therapeutic effect of rabbit gouty arthritis due to the micro-crystal type uric acid sodium
Irritate stomach to rabbit and be equivalent to raw medicinal herbs 4.0g/kg, 2.0g/kg and behind the medicine of the present invention of 1.0g/kg (claiming " mountain yellow capsule " again), adopt micro-crystal type uric acid sodium to cause the rabbit acute gouty arthritis, 2～6 hours paw swelling of high dose group animal and blank group are relatively, remarkable reduction (P＜0.05～0.001) is all arranged, and inflammatory mediator IL-1 β level is than the obvious reduction of model group in each dosage treated animal serum of administration, histopathologic examination's display model treated animal joint synovitis disease as a result is obvious, synovial cell proliferation is also obvious, little blood vessel hyperplasia and fibrin ooze out all obvious, and yellow capsule each administration group in mountain has clear improvement than the model group pathological condition.Above result shows that the mountain yellow capsule has certain preventive and therapeutic effect for the rabbit acute gouty arthritis that micro-crystal type uric acid sodium causes.The result shows: the mountain yellow capsule of irritating the stomach doses causes the rabbit gouty arthritis to micro-crystal type uric acid sodium and has certain antiinflammatory action.
3, pharmaceutical composition of the present invention is to the granulomatous inhibitory action of rat agar
Adopt the struvite agar granuloma of rat chronic method, behind the yellow capsule of rat filling in continuous 10 days stomach mountain, high, middle dosage (8.0,4.0 crude drugs/kg) compare with model control group, and remarkable reduction is all arranged by the granuloma weight in wet base of treated animal.Prompting mountain yellow capsule has the obvious suppression effect to the struvite agar granuloma of rat chronic.
4, the inhibitory action of white mice auricle edema due to the pharmaceutical composition xylol of the present invention
Adopt the scorching method of white mice auricle caused by dimethylbenzene xylene, give mouse stomach mountain yellow capsule 16g/kg, 8g/kg and 4g/kg, the result shows: the auricle swelling degree of high, middle dosage treated animal and model control group are relatively, remarkable reduction (P＜0.05) is all arranged, and the acute auricle edema of prompting this product xylol induced mice has tangible antiinflammatory action.
5, pharmaceutical composition of the present invention is to the analgesic activity (writhing method) of white mice
Behind the mountain yellow capsule of mice lavage administration 16g/kg, 8g/kg and 4g/kg, the body number of times of turning round that causes because of lumbar injection 0.5% acetic acid all has remarkable minimizing (P＜0.001) than blank group, the mice of wherein high, middle dosage group, obviously prolong (P＜0.05～0.01) than blank group the incubation period of turning round body.Show that this product has analgesic activity to the mice pain that lumbar injection acetic acid causes.
6, pharmaceutical composition of the present invention is to the analgesic activity (hot plate method) of white mice
Behind the mountain yellow capsule of mice lavage administration 16g/kg, 8g/kg and 4g/kg, the animal of high, middle dosage group has significant prolongation because of the time ratio blank group that is subjected to thermostimulation to produce pain reaction, and wherein the mice of high dose group all obviously prolonged (P＜0.05～0.001) than blank group in 2～3 hours behind 1～3 hour, the administration of middle dosage group mouse stomach behind the gastric infusion.Show that this product is to having analgesic activity because of the mice pain that caused by thermostimulation.
7, pharmaceutical composition of the present invention is to the analgesic activity (tail-flick method) of rat
Mountain yellow capsule 1h～3h of rat gastric infusion 8g/kg, 4g/kg is through finding that with the tail-flick method test pain threshold of animal all has significant prolongation (P＜0.01～0.001) in the whipping time than blank group; Demonstrate significant analgesia role (P＜0.05), then not obvious behind the 3h (P＞0.05) behind the mountain yellow capsule low dosage 2g/kg administration 2h.Above result shows that the mountain yellow capsule has significant analgesia role to rat.
Acute toxicity test in mice: the mountain yellow capsule does not see tangible acute toxic reaction for the mouse stomach administration, can't measure median lethal dose(LD 50) (LD50) according to a conventional method.The maximum dosage-feeding of mice gastric infusion on the one is 144.0g crude drug/kg, and this dosage is equivalent to intend 240 times of clinical people's consumption, does not see tangible toxic reaction.
The rat long term toxicity test: 3 months long term toxicity test of the continuous gastric infusion of rat studies show that, give SD rat continuous irrigation stomach 90 days with the mountain yellow capsule that is equivalent to raw medicinal herbs 22.5,15.0 and 10.0g/kg dosage, wherein heavy dose ofly be about clinical people and intend 37.5 times with dosage, do not find that animal has phenomenons such as movable minimizing, Mao Songluan, listlessness be depressed, food-intake, organ coefficient, hematology and the histopathologic examination etc. of rat be there is no tangible toxic reaction.But blood biochemical is learned and is checked that 3 months AST of demonstration heavy dose of group administration obviously raises, dosage group body weight gain big or middle is starkly lower than the blank group, and the feces of heavy dose of group rat soft rare (but basic shaping) illustrates this product heavy dose, takes and have certain toxic reaction for a long time; But small dose group is then seen overt toxicity is not arranged, show that (10.0g crude drug/kg) is following to be safe dose for the low dose of this product rat long term toxicity test, doses over long periods big or middle is used has certain toxicity, notes the monitoring of dosage design and blood parameters when submitting clinical use to.Convalescent period each administration treated animal all no abnormal change of AST, and convalescent period body weight return to substantially normally, the prompting toxic reaction the phenomenon drug withdrawal after can recover naturally, can not cause serious harm.The result shows that this product uses basic security in clinical plan with under the dosage.
Learn test through toxicology and pharmacology, technical scheme of the present invention and the no obvious toxic and side effects of prescription are taken safety, and this product has tangible analgesia, antiinflammatory, detumescence effect.
The specific embodiment
Below in conjunction with embodiment the present invention is further described:
Embodiment 1: a kind of pharmaceutical composition for the treatment of acute gouty arthritis and preparation method thereof
(1), the pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Cortex Phellodendri 40g;
Radix Scutellariae 40g;
Radix Et Rhizoma Rhei 40g;
Radix Stephaniae Tetrandrae 40g;
Rhizoma Smilacis Glabrae 120g;
Pseudobulbus Cremastrae Seu Pleiones 120g.
(2), preparation method:
Get Cortex Phellodendri and Radix Stephaniae Tetrandrae and add 60% alcohol reflux extraction 2 times, each 1.5 hours, add 10 times of amount ethanol for the first time, add 8 times of amount ethanol for the second time.Get Radix Et Rhizoma Rhei, Radix Scutellariae and add 65% alcohol reflux and extract three times, add 10 times of amount ethanol for the first time, second and third time respectively adds 8 times of amount ethanol, each 1.5h.Fetch earth Poria, Pseudobulbus Cremastrae Seu Pleiones extracting in water add 12 times of water gagings for the first time, add 10 times of water gagings for the second time, decoct each 1 hour 2 times.Alcohol extract merges after reclaiming ethanol respectively, merges with water extracting liquid, and spray drying is granulated, and encapsulated, perhaps after the spray drying, centrifugal-fluidization process prepares micropill, and is encapsulated.
Embodiment 2: a kind of pharmaceutical composition for the treatment of acute gouty arthritis and preparation method thereof
(1), the pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Cortex Phellodendri 50g;
Radix Scutellariae 30g;
Radix Et Rhizoma Rhei 60g;
Radix Stephaniae Tetrandrae 40g;
Rhizoma Smilacis Glabrae 100g;
Pseudobulbus Cremastrae Seu Pleiones 100g.
(2), preparation method: prescription Cortex Phellodendri, Radix Scutellariae, Radix Et Rhizoma Rhei, Radix Stephaniae Tetrandrae alcohol extraction, concentrate, solid-liquid separation, Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones water extraction, solid-liquid separation, drying, granulation, encapsulated.
Embodiment 3: a kind of pharmaceutical composition for the treatment of acute gouty arthritis and preparation method thereof
(1), the pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Cortex Phellodendri 60g;
Radix Scutellariae 70g;
Radix Et Rhizoma Rhei 40g;
Radix Stephaniae Tetrandrae 40g;
Rhizoma Smilacis Glabrae 100g;
Pseudobulbus Cremastrae Seu Pleiones 110g.
(2), preparation method: each medicinal water extraction of writing out a prescription, concentrate, solid-liquid separation, drying is granulated, and is encapsulated.
The clinical practice example:
" the mountain yellow capsule " that adopt the present invention's development based on for oral administration, treatment acute gouty arthritis 30 examples, and with 30 examples of allopurinol treatment in contrast, obtain satisfactory effect, now be reported as follows:
1. clinical data: observe 60 examples and be the outpatient of the court, be divided into two groups at random.30 examples are organized in treatment, male 26 examples; The woman, 4 examples; 38～67 years old age, average 49 years old; The course of disease 25 days～15 years average 3 years 4 months, is wherein invaded metatarsophalangeal joints 21 examples, ankle joint 13 examples, other joint 6 examples, blood uric acid 408.5～658.0umol/L, average 530umol/L.Matched group 30 examples, male 28 examples, women 2 examples; 41～68 years old age, average 50.5 years old; The course of disease 15 days～6 years average 3 years 2 months, is wherein invaded metatarsophalangeal joints 25 examples, ankle joint 7 examples, other 5 examples; Blood uric acid 411.0～687.5umol/L, (the blood uric acid normal value is 150～430umol/L) to average 528umol/L.All capable liver function test before and after all case treatments, liver function is normal.No significant differences such as two groups of case age distribution, the course of disease, hematuria acid number, two groups of clinical datas have comparability.
2. diagnostic criteria
2.1 diagnostic criteria: more than the outbreak once of (1) acute arthritis, in 1 day, reach the outbreak peak with reference to the formulation in 1977 of rheumatoid disease association; (2) acute arthritis is confined to indivedual joints; (3) whole joint is kermesinus; The multitudinous arthralgia of (4) the 1st big toes foot; (5) the scorching acute attack of one-sided tarsal joint; (6) tophus is arranged; (7) hyperuricemia; (8) asymmetry joint tumor; (9) outbreak can be ended voluntarily.All possess this standard more than 4, and the person that can get rid of the secondary gout, promptly diagnosable.
2.2 Chinese medical discrimination belongs to pyretic arthralgia (damp and hot arthralgia due to blood stasis sun) person; Card is seen: joint (monopodia or biped metatarsophalangeal joints are seen more) red, swollen, burning pain, joint stuffiness; Meet the heat aggravation, get cold easypro slightly; Many night-time attacks, pain is acute, and severe patient involves ankle and other little joints, and the heat that occurs together, xerostomia, yellowish urine are red, yellow and greasy fur, slippery and rapid pulse.
3. Therapeutic Method
The treatment group: 2 of " mountain yellow capsule " prescriptions (form: Cortex Phellodendri, Radix Scutellariae, Radix Et Rhizoma Rhei, Radix Stephaniae Tetrandrae, Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones), every day 3 times is oral.
Matched group: with allopurinol 0.1g, every day 3 times is oral; Vit B1 20mg, every day 3 times is oral, heating and urinary system calculus person anti symptom treatment.
Two groups is 1 course of treatment to treat 7 days all, adds up therapeutic outcome after 2 courses of treatment.
4. observation of curative effect
4.1 criterion of therapeutical effect
The recovery from illness: clinical symptoms all disappears, joint motion freely, blood uric acid is reduced to normally.
Produce effects: clinical symptoms takes a turn for the better, and joint motion is flexible, and the more preceding reduction of blood uric acid is more than 10%.
Invalid: clinical symptom remission is not obvious, blood uric acid and the preceding no significant change of treatment.
4.2 therapeutic outcome
All cases are made evaluation in equal 2 courses of treatment, and therapeutic outcome is as table.
| Group | Recovery from illness | Produce effects | Invalid | Add up to | Total effective rate |
| Treatment group matched group | 16 11 | 12 11 | 2 7 | 30 30 | 93.3％ 71.3％ |
Give rank test P＜0.05, significant difference is arranged, curative effect treatment group is better than matched group.
4.2.1 blood uric acid decline result is relatively before the treatment:
Blood uric acid 130.18 ± the 12.20umol/L that on average descends in treatment back wherein reduces to normal person's 16 examples, 10% above person's 11 examples that descend, no significant change person's 2 examples.
Blood uric acid descends before and after the treatment, learns by statistics and handles P＜0.05.
The hepatic and renal function chemical examination is all normal before and after the treatment.
Use the t check of pairing design value data before and after the treatment.
4.2.2 arthralgia improves relatively.
After 2 course of therapy, arthralgia 16 examples that disappear, 11 examples that take a turn for the better, invalid 2 examples.
5. discuss
Mostly acute arthritis is that first symptom of gout shows as with the local redness and swelling of joints burning pain of lower limb to being characterized as inflammatory reaction, and characteristic shows as the acute inflammatory reaction of caused joint of uric acid sodium crystallization and surrounding soft tissue thereof on the pathology.Clinical treatment lacks specific radical cure method based on antiinflammatory.Though Western medicine allopurinol may command symptom reduces blood uric acid; But gastrointestinal reaction is once arranged, liver injury, side effect such as skeleton inhibition, and easily recurrence.
The Chinese medicine gout has unique theoretical system and clinical advantage.According to its disease type characteristics, " arthromyodynia " categories that belong to more, comprehensive literature report, the traditional Chinese medical science is tended to two kinds of viewpoints to the understanding of acute gouty arthritis more: the one, think person in middle and old age's obese males, eating and drinking without temperance, surfeit rich and fatty diet usually, retention of damp-heat in the interior, the diseases caused by exogenous pathogenic factor ailment said due to cold or exposure of holding concurrently, QI and blood is not smooth, dampness and heat stasis meridians and falling ill.The 2nd, think primary disease because the evil meridians of invading of wind and cold prison impregnate the joint, with the passing of time heat-transformation, the dampness and heat stasis passages through which vital energy circulates forms, and its pathogenesis key is: the rheumatic fever stasis of blood, numbness resistance meridians (dampness and heat stasis) are so suitable heat clearing and damp drying pathogenic fire purging, clots absorbing removing obstruction in the collateral to relieve pain are gone up in treatment.
Modern medicine study Cortex Phellodendri, Radix Stephaniae Tetrandrae are the anti-inflammatory medicine with heat clearing away effect, the inflammatory reaction in the time of can alleviating the gouty arthritis acute attack.The contained big fitoncidin of Radix Et Rhizoma Rhei has stronger inhibitory action to the fast oxidase of holding in the mouth or the eyes of Huang, can reduce the synthetic of uric acid.But Radix Et Rhizoma Rhei relieving constipation in addition, can promote uric acid to discharge from stool, Rhizoma Smilacis Glabrae has certain uricotelism, Pseudobulbus Cremastrae Seu Pleiones has the effect of autumn waters--limid eyes choline sample, can suppress leukocyte chemotaxis, alleviate the acute gouty arthritis inflammatory reaction, Pseudobulbus Cremastrae Seu Pleiones has the hard masses softening and resolving effect in addition, urate crystal and tophus former effect shown experimental results show that, with Cortex Phellodendri, Radix Scutellariae, Radix Et Rhizoma Rhei, Radix Stephaniae Tetrandrae, Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones prescription, by heat-clearing and toxic substances removing, clots absorbing purges heat according to theory of Chinese medical science, aspect synergism such as reducing swelling and alleviating pain have reached treatment acute gouty arthritis purpose.
Claims (10)
1, a kind of pharmaceutical composition for the treatment of acute gouty arthritis is characterized in that mainly being made up of the crude drug of following parts by weight:
Cortex Phellodendri or Rhizoma Coptidis 1-15 part;
Radix Scutellariae 1-15 part;
Radix Et Rhizoma Rhei 1-15 part;
Radix Stephaniae Tetrandrae 1-13 part;
Rhizoma Smilacis Glabrae 5-25 part;
Pseudobulbus Cremastrae Seu Pleiones 5-25 part.
2, pharmaceutical composition according to claim 1 is characterized in that: Cortex Phellodendri is a Cortex Phellodendri in the described crude drug.
3, pharmaceutical composition according to claim 2 is characterized in that: the consumption of described each crude drug is:
Cortex Phellodendri 2-6 part;
Radix Scutellariae 2-5 part;
Radix Et Rhizoma Rhei 2-8 part;
Radix Stephaniae Tetrandrae 2-7 part;
Rhizoma Smilacis Glabrae 10-15 part;
Pseudobulbus Cremastrae Seu Pleiones 10-15 part.
4, pharmaceutical composition according to claim 2 is characterized in that: the consumption of described each crude drug is:
Cortex Phellodendri 3-4 part;
4 parts of Radix Scutellariaes;
Radix Et Rhizoma Rhei 4-6 part;
Radix Stephaniae Tetrandrae 4-5 part;
Rhizoma Smilacis Glabrae 12-14 part;
Pseudobulbus Cremastrae Seu Pleiones 11-13 part.
5, according to the described preparation of drug combination method of one of claim 2-4, it is characterized in that: comprise the steps: earlier Cortex Phellodendri, Radix Scutellariae, Radix Et Rhizoma Rhei, Radix Stephaniae Tetrandrae, Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones, water and/or alcohol extraction, concentrated extracting solution finally obtains any preparation on the pharmaceutics then.
6, preparation of drug combination method according to claim 5, it is characterized in that: to the Cortex Phellodendri in the crude drug, Radix Stephaniae Tetrandrae, Radix Scutellariae, Radix Et Rhizoma Rhei alcohol extraction, Rhizoma Smilacis Glabrae, Pseudobulbus Cremastrae Seu Pleiones water extraction, concentrated extracting solution then, merge water extract and alcohol extract, drying.
7, preparation of drug combination method according to claim 6 is characterized in that: comprise the steps:
(1), get Cortex Phellodendri, Radix Stephaniae Tetrandrae medical material, add alcohol reflux and extract, pure liquid, further concentrate pure liquid, alcohol extraction concentrated solution A;
(2), get Radix Et Rhizoma Rhei, radix scutellariae medicinal materials, add that alcohol reflux extracts and concentrate alcohol extraction concentrated solution B;
(3), the Poria that fetches earth, Pseudobulbus Cremastrae Seu Pleiones medical material, extracting in water and concentrate water extracting liquid C;
(4), concentrated solution A, B, C are merged, drying is granulated or pill, the active component of pharmaceutical composition of the present invention.
8, preparation of drug combination method according to claim 7 is characterized in that: described pure liquid is ethanol liquid, and weight percent concentration is 55%---95%.
9, preparation of drug combination method according to claim 7 is characterized in that: described method of granulating is wet granulation or dry granulation or spray-drying process or fluidized bed granulation.
10, preparation of drug combination method according to claim 7 is characterized in that: described pill method is for extruding spheronization or centrifugal-fluidization process or coating pan method or the granulating coated method of ebullated bed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100226812A CN100384462C (en) | 2005-12-21 | 2005-12-21 | Medicinal composition for treating acute urarthritis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100226812A CN100384462C (en) | 2005-12-21 | 2005-12-21 | Medicinal composition for treating acute urarthritis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1824204A true CN1824204A (en) | 2006-08-30 |
| CN100384462C CN100384462C (en) | 2008-04-30 |
Family
ID=36935148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100226812A Expired - Fee Related CN100384462C (en) | 2005-12-21 | 2005-12-21 | Medicinal composition for treating acute urarthritis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100384462C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249173B (en) * | 2008-04-07 | 2010-08-18 | 杨漓 | Traditional Chinese medicine preparation for curing gout and method of preparing the same |
| CN102755598A (en) * | 2012-08-02 | 2012-10-31 | 侯可强 | Medicine for treating acute gouty arthritis and preparation method thereof |
| CN106421376A (en) * | 2015-08-08 | 2017-02-22 | 葛以东 | Arthrolithiasis treatment food therapy formula |
| CN111956754A (en) * | 2020-09-17 | 2020-11-20 | 楚雄彝族自治州中医医院 | Yi nationality medicine for acute stage of gout |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1273180C (en) * | 2004-09-21 | 2006-09-06 | 亿利资源集团公司 | Medicine for treating arthritis |
-
2005
- 2005-12-21 CN CNB2005100226812A patent/CN100384462C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249173B (en) * | 2008-04-07 | 2010-08-18 | 杨漓 | Traditional Chinese medicine preparation for curing gout and method of preparing the same |
| CN102755598A (en) * | 2012-08-02 | 2012-10-31 | 侯可强 | Medicine for treating acute gouty arthritis and preparation method thereof |
| CN106421376A (en) * | 2015-08-08 | 2017-02-22 | 葛以东 | Arthrolithiasis treatment food therapy formula |
| CN111956754A (en) * | 2020-09-17 | 2020-11-20 | 楚雄彝族自治州中医医院 | Yi nationality medicine for acute stage of gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100384462C (en) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1250255C (en) | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1803177A (en) | Chinese medicinal composition for treating gout and its preparing process | |
| CN1712054A (en) | Qinchuan Tongbi tablet | |
| CN1286502C (en) | Medicine for treating gout affection and its symptoms | |
| CN1824204A (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN1927322A (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN104258051B (en) | Traditional Chinese medicine composition for treating gouty arthritis, and preparation method thereof | |
| CN101049360A (en) | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN1240412C (en) | Chinese medicine compound preparation for treating piles and preparing process thereof | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN102335362B (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN101757369A (en) | Medicine composition for treating acute goutry arthritis and preparation process thereof | |
| CN115845003B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating arthritis | |
| CN1301728C (en) | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method | |
| CN109758505B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process | |
| CN1660329A (en) | Medication of possessing effect for reducing fat and treating fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080430 Termination date: 20151221 |
|
| EXPY | Termination of patent right or utility model |